The “Unlimited Energy” Peptide Stack: An Evidence Check
Five research peptides grouped around one hypothesis — supporting cellular energy and recovery. That idea is untested: no cited study measured energy, fatigue, or ATP output in humans. SS-31 and MOTS-c are studied for mitochondrial effects; CJC-1295/Ipamorelin act on the GH/IGF-1 axis; BPC-157 and TB-500 are studied, mainly in animals, for tissue repair.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar — your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
What's in the Stack
SS-31 (elamipretide) concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, the lipid that organizes the electron-transport chain. Protecting cardiolipin is proposed to support ATP production. Small Phase 2 heart-failure trials did not meet their primary endpoint (e.g., PROGRESS-HF in HFrEF, PMID 32068002), and in September 2025 the FDA granted elamipretide accelerated approval as Forzinity to improve muscle strength in Barth syndrome. Dosing for Barth syndrome is set by the FDA label (Drugs@FDA, NDA 215244); no dose is established for any other use.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK — the same energy-sensor exercise triggers. In humans, muscle MOTS-c rises ~11.9× after a single bout of exercise (Reynolds 2021); in aged mice it roughly doubled treadmill capacity. Almost entirely preclinical.
A GHRH analog (CJC-1295) plus a selective GHRP (Ipamorelin) is used to raise GH secretion; the cited studies measured GH, IGF-1, ACTH, and cortisol, not sleep. In Teichman 2006 a single CJC-1295 DAC dose kept GH elevated 6+ days and IGF-1 elevated 9–11 days in healthy adults. In swine, ipamorelin released GH without raising ACTH or cortisol (Raun 1998).
BPC-157, a pentadecapeptide from gastric juice, has been studied mainly in animals for gut, vascular, and connective-tissue repair. The evidence is overwhelmingly preclinical; the human data cited here is an IV safety pilot in two adults (PMID 40131143).
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a G-actin–sequestering protein. The repair data usually cited for it come mostly from full-length Tβ4: in mice after coronary ligation, Tβ4 enhanced early cardiomyocyte survival and improved cardiac function (Bock-Marquette 2004), and in diabetic and aged mice it accelerated dermal wound repair (Philp 2003). Human Tβ4 trials are few and used full-length thymosin β4 (e.g., eye drops for severe dry eye, Sosne 2015); none tested TB-500. The BPC-157 + TB-500 pairing is popular but has zero human RCTs.
What the Data Shows
How the Stack Is Described in Research-Use Reports
This table describes how the stack is discussed in research-use reports; it is not a schedule to follow or a recommendation to take any of these compounds. Community dose figures are not listed because none has been tested in trials. None of these uses is FDA approved.
Key Takeaways
- Two of the five peptides have human efficacy or pharmacokinetic trials of note: SS-31/elamipretide was tested in small Phase 2 heart-failure trials that did not meet their primary endpoint (PROGRESS-HF, PMID 32068002) and, as Forzinity, is FDA-approved (accelerated approval, 2025) for muscle strength in Barth syndrome only, and CJC-1295 DAC has a published human pharmacokinetic study (Teichman 2006, PMID 16352683).
- MOTS-c is exercise-induced: human muscle MOTS-c rises ~11.9× after a single bout of exercise (Reynolds, Nature Communications 2021, PMID 33473109), and it activates AMPK, the same energy sensor exercise triggers (Lee et al., Cell Metabolism 2015, PMID 25738459).
- A single CJC-1295 DAC injection elevated GH for 6+ days and IGF-1 for 9–11 days, and in swine Ipamorelin released GH without raising ACTH or cortisol (Raun 1998, PMID 9849822).
- BPC-157 has been studied mainly in animals; the human data cited here is an IV safety pilot in two adults (doses up to 20 mg) that reported no adverse effects (PMID 40131143).
- TB-500 is a synthetic fragment of thymosin beta-4, a G-actin–sequestering protein, but the repair data come mostly from the full-length protein: Bock-Marquette 2004 (PMID 15565145) showed thymosin beta-4 enhanced early cardiomyocyte survival and improved cardiac function after coronary ligation in mice, and Philp 2003 (PMID 12581423) showed accelerated dermal wound repair in diabetic and aged mice.
- No human trial has ever tested these five peptides together as a stack. Every claimed synergy is theoretical, not measured.
- Three of the five — MOTS-c, BPC-157, and TB-500 — rest almost entirely on animal and in-vitro data. Rodent results do not reliably predict human outcomes.
- None of these peptides is FDA approved for energy, performance, or recovery. Elamipretide (SS-31) has one FDA approval: Forzinity (September 2025, accelerated approval) to improve muscle strength in Barth syndrome, a rare inherited mitochondrial disease, in patients weighing at least 30 kg (Drugs@FDA, NDA 215244) — not for energy, heart failure, or general use; human Tβ4 trials are few and used full-length thymosin β4 (e.g., Sosne 2015, PMID 25826322); none tested TB-500.
- Long-term safety of chronic GH/IGF-1 stimulation is unsettled.
- There is no validated combined dosing schedule. The cadences here are extrapolated from each compound’s individual research-use reports, not from a trial of the stack.
- Quality and purity of research peptides vary widely between sources; nothing here is a recommendation to obtain or self-administer any of these compounds.
Frequently Asked Questions
What is the Unlimited Energy Stack?
It is a research-oriented combination of five peptides grouped around the untested idea of supporting cellular energy and recovery: SS-31 and MOTS-c are studied for mitochondrial effects, CJC-1295 with Ipamorelin act on the GH/IGF-1 axis, and BPC-157 with TB-500 are studied, mainly in animals, for tissue repair. It is a conceptual framework drawn from the individual compounds — not an FDA-approved or clinically validated protocol.
Which peptides in the stack actually have human data?
Two have human trials of note. SS-31 (elamipretide) was tested in small Phase 2 heart-failure trials that did not meet their primary endpoint (e.g., PROGRESS-HF), and in September 2025 the FDA granted elamipretide accelerated approval as Forzinity to improve muscle strength in Barth syndrome. CJC-1295 DAC has a published human pharmacokinetic study in healthy adults (Teichman 2006). MOTS-c, BPC-157, and TB-500 rely overwhelmingly on animal and in-vitro research, with only small human pilots for BPC-157; human thymosin β4 trials used the full-length protein, not TB-500.
How are SS-31 and MOTS-c thought to differ?
SS-31 protects cardiolipin in the inner mitochondrial membrane, which is proposed to support ATP production. MOTS-c is a mitochondrial-derived peptide that activates AMPK and has been described as an exercise mimetic based on mouse studies — in humans, exercise itself raises muscle MOTS-c about 11.9-fold after a single bout, but giving MOTS-c has not been shown to reproduce exercise effects in people.
Why include CJC-1295 and Ipamorelin in an energy stack?
The stack’s rationale is that energy depends on recovery as well as production; that link is untested. CJC-1295 (a GHRH analog) plus Ipamorelin (a selective GHRP) raises growth-hormone secretion, with IGF-1 thought to support tissue recovery. In Teichman 2006, one CJC-1295 DAC dose kept GH elevated 6+ days and IGF-1 elevated 9–11 days, and in swine Ipamorelin released GH without raising ACTH or cortisol (Raun 1998).
Why are BPC-157 and TB-500 paired?
The pairing is usually justified by the two being studied for different kinds of repair: BPC-157 is studied, mostly in animals, for gut, vascular, and local connective-tissue repair, while TB-500 is a synthetic fragment of thymosin beta-4, a G-actin–sequestering protein whose cell-migration and repair data (mouse heart and skin-wound studies) come mostly from the full-length protein. The pairing is popular in the research community, but no human randomized trial has tested the combination.
Is this stack proven or safe?
No combined human trial of these five peptides exists, and none is FDA approved for energy or recovery. Three of the five are almost entirely preclinical. Long-term safety of chronic GH/IGF-1 stimulation is unsettled. This page is educational only and not a recommendation to use any of these compounds.
Swiss Chems (affiliate partner)
HighPeptides earns a commission on purchases. Lab-test standing and regulatory notices for every vendor we track, including this one, are on our vendors page.
Visit Swiss Chems (affiliate) →Affiliate links — support HighPeptides at no extra cost.
🛒 Lab Supplies
General lab supplies (affiliate). Listing them is not a recommendation to obtain or use any compound on this page.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Our 47-page peptide reference ebook, sold separately. Nothing in it changes this page: no dose for this stack has been tested in trials.
Get the guide — $19 (normally $29) → New to peptides? Start with the $19 Buyer’s Playbook → All ebooks & guides →Educational purposes only. Not medical advice.
None of the five peptides in this stack is FDA approved for energy, performance, or recovery, and no human trial has tested the combination. SS-31, MOTS-c, CJC-1295, Ipamorelin, BPC-157, and TB-500 are research compounds. Nothing here is a recommendation to obtain or self-administer them.
Figures are cited from peer-reviewed sources reused from our individual compound pages: Reynolds et al., Nature Communications 2021 (PMID 33473109); Lee et al., Cell Metabolism 2015 (PMID 25738459); Teichman et al., JCEM 2006 (PMID 16352683); Raun et al., Eur J Endocrinol 1998 (PMID 9849822); Bock-Marquette et al., Nature 2004 (PMID 15565145); Philp et al., Wound Repair Regen 2003 (PMID 12581423); Sosne et al., Cornea 2015 (PMID 25826322). Consult a qualified healthcare provider before any intervention.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.